Corsera Health

Corsera Health develops preventive RNA interference medicines focused on reducing cardiovascular disease risk before long-term damage occurs. The company’s approach targets two biological drivers of cardiovascular disease by silencing PCSK9 to lower LDL cholesterol and AGT to reduce blood pressure. Its RNAi platform works by decreasing the production of these proteins at the gene expression level, aiming to alter disease progression through early intervention. Corsera Health designs its medicines for once-yearly administration to support long-term adherence and simplify preventive care. The company’s development strategy emphasizes broad population use and accessibility through scalable manufacturing and pricing structures suited for preventive treatment.

Domain

corserahealth.com

Employees

11-50

Last Funding

$80.0M

Founded

2025

Frequently Asked Questions

What technologies does Corsera Health use?+

Corsera Health uses 11 technologies including Google Analytics, Google Tag Manager, Bunny Fonts.

What industry is Corsera Health in?+

Corsera Health operates in the Biotechnology industry.

Where is Corsera Health based?+

Corsera Health is headquartered in United States.

Need this data at scale?

Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.

Browse Datasets

Data last updated: June 2026